Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT03090165 2026-01-02

Ribociclib and Bicalutamide in AR+ TNBC

Phase 1/2 Active not recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

18 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT02555189 2024-05-13

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Completed

46 enrolled

Genitourinary

Prostatic Neoplasms

NCT01543698 2024-03-13

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Phase 1/2 Completed

189 enrolled 44 charts

Other solid neoplasm

Solid Tumors Harboring a BRAF V600 Mutation

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Phase 1/2 Completed

43 enrolled 22 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02657343 2022-08-01

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase 1/2 Completed

25 enrolled 16 charts

Breast

Breast Neoplasms

NCT03913234 2022-05-10

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Phase 1/2 Unknown

95 enrolled

Breast

Breast Neoplasms

NCT02732119 2021-05-05

TRINITI-1

Phase 1/2 Completed

104 enrolled 24 charts

Breast

Breast Neoplasms

NCT02607124 2020-11-05

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

Phase 1/2 Terminated

11 enrolled 10 charts

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT01777776 2016-09-13

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Phase 1/2 Terminated

28 enrolled 14 charts

Dermatologic

Melanoma

Clinical Trials

CALHYS

KontRASt-03

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

CYCAD-1

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Morpheus-panBC

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

PIKALO-1

ESMART

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

ELEVATE

Ribociclib and Bicalutamide in AR+ TNBC

Study of AVZO-021 in Patients With Advanced Solid Tumors

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

TRINITI-1

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.